Neulasta
FDA Approves Stimufend, Biosimilar for Neulasta
The FDA approved Stimufend, a biosimar for Neulasta, for patients with non-myeloid malignancies receiving ...
SEPTEMBER 7, 2022
FDA Approves Fulphila, First Biosimilar to Neulasta
Mylan's Fulphila is the first biosimilar to Neulasta to decrease the chance of infection as suggested by febrile ...
JUNE 4, 2018
Load more